Seeking Alpha
20 Nov 2026, 04:34 UTC · 55m ago
Sagimet: New Acne Medication In 40 Years (Initiating With A Buy)
Impact · against what's priced in
Sagimet is initiated as a Buy based on its cash position and China-based efficacy data for denifanstat. While the 2H27 AURORA data readout is the primary catalyst, the current valuation is viewed as an undervaluation of the validated asset.
- SGMT+0.60
No priced-in read yet
- In context
The company has a fully funded path to 2H27 data readouts with $356 million in cash and a treatment success rate of 33.2% in China compared to 14.6% for placebo.
Read from the article alone

Top 1 mover · tap to explore




